|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang Y, Gu J, Roth JA, Hildebrandt MA,
Lippman SM, Ye Y, Minna JD and Wu X: Pathway-based serum microRNA
profiling and survival in patients with advanced stage non-small
cell lung cancer. Cancer Res. 73:4801–4809. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ourari-Dhahri B, Ben Slima H, Ben Amar J,
El Gharbi L, Ali M, Azzabi Baccar S, Aouina H and Bouacha H:
Management of non small cell lung cancer. Tunis Med. 90:847–851.
2012.(In French). PubMed/NCBI
|
|
4
|
Kuner R, Muley T, Meister M, Ruschhaupt M,
Buness A, Xu EC, Schnabel P, Warth A, Poustka A, Sültmann H and
Hoffmann H: Global gene expression analysis reveals specific
patterns of cell junctions in non-small cell lung cancer subtypes.
Lung Cancer. 63:32–38. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Esteban E, Casillas M and Cassinello A:
Pemetrexed in first-line treatment of non-small cell lung cancer.
Cancer Treat Rev. 35:364–373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peng X, Guo W, Ren T, Lou Z, Lu X, Zhang
S, Lu Q and Sun Y: Differential expression of the RANKL/RANK/OPG
system is associated with bone metastasis in human non-small cell
lung cancer. PLoS One. 8:e583612013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kong YY, Feige U, Sarosi I, Bolon B,
Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, et al:
Activated T cells regulate bone loss and joint destruction in
adjuvant arthritis through osteoprotegerin ligand. Nature.
402:304–309. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Harada S and Takahashi N: Control of bone
resorption by RANKL-RANK system. Clin Calcium. 21:1121–1130.
2011.(In Japanese). PubMed/NCBI
|
|
9
|
Hanada R, Hanada T, Sigl V, Schramek D and
Penninger JM: RANKL/RANK-beyond bones. J Mol Med (Berl).
89:647–656. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peters S and Meylan E: Targeting receptor
activator of nuclear factor-kappa B as a new therapy for bone
metastasis in non-small cell lung cancer. Curr Opin Oncol.
25:137–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fluss R, Faraggi D and Reiser B:
Estimation of the Youden Index and its associated cutoff point.
Biom J. 47:458–472. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Diamandis EP, Goodglick L, Planque C and
Thornquist MD: Pentraxin-3 is a novel biomarker of lung carcinoma.
Clin Cancer Res. 17:2395–2399. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wiedemann GJ: Biomarker screening for
early detection of cance. Dtsch Med Wochenschr. 138:43–45. 2013.(In
German). PubMed/NCBI
|
|
15
|
Ferrigno D, Buccheri G and Giordano C:
Neuron-specific enolase is an effective tumour marker in non-small
cell lung cancer (NSCLC). Lung Cancer. 41:311–320. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Strathmann FG, Schulte S, Goerl K and
Petron DJ: Blood-based biomarkers for traumatic brain injury:
Evaluation of research approaches, available methods and potential
utility from the clinician and clinical laboratory perspectives.
Clin Biochem. 47:876–888. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ibrahim T, Sacanna E, Gaudio M, Mercatali
L, Scarpi E, Zoli W, Serra P, Ricci R, Serra L, Kang Y and Amadori
D: Role of RANK, RANKL, OPG and CXCR4 tissue markers in predicting
bone metastases in breast cancer patients. Clin Breast Cancer.
11:369–375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dougall WC and Chaisson M: The
RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer
Metastasis Rev. 25:541–549. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Owen S, Ye L, Sanders AJ, Mason MD and
Jiang WG: Expression profile of receptor activator of nuclear-κB
(RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast
cancer. Anticancer Res. 33:199–206. 2013.PubMed/NCBI
|
|
20
|
Karapanagiotou EM, Terpos E, Dilana KD,
Alamara C, Gkiozos I, Polyzos A and Syrigos KN: Serum bone turnover
markers may be involved in the metastatic potential of lung cancer
patients. Med Oncol. 27:332–338. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Silva I and Branco JC: Rank/Rankl/opg:
Literature review. Acta Reumatol Port. 36:209–218. 2011.PubMed/NCBI
|
|
22
|
Shu J, Li CG, Liu YC, Yan XC, Xu X, Huang
XE, Cao J, Li Y, Lu YY, Wu XY, et al: Comparison of serum tumor
associated material (TAM) with conventional biomarkers in cancer
patients. Asian Pac J Cancer Prev. 13:2399–2403. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Prisadov GT, Uchikov AP, Welker K,
Wallimann H, Murdzhev KA and Uzunova VN: Size of tumour as a risk
factor for malignancy in patients with peripheral pulmonary
nodules. Folia Med (Plovdiv). 54:17–21. 2012.PubMed/NCBI
|
